Trials / Unknown
UnknownNCT02133079
Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Cure&Sure Biotech Co., LTD · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and Pancreatic Adenocarcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | autologous gp96 vaccination | vaccination of autologous gp96 derived from tumor tissue + basal treatment |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2016-11-01
- Completion
- 2019-11-01
- First posted
- 2014-05-07
- Last updated
- 2015-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02133079. Inclusion in this directory is not an endorsement.